3Gnudi L, Thomas SM, Viberti G. Mechanical forces in diabetic kid- ney disease: a trigger for impaired glucose metabolism [J]. J Am Soc Nephrol,2007, 18 (8) : 2226 - 2232.
4Daroux M, Pr6vost G, Maillard - Lefebvre I-I, et at. Advanced glyca- tion end - products: implications for diabetic and non - diabetic ne-phropathies[ J ]. Diabetes Metab ,2010,36 ( 1 ) :1 - 10.
7Hawai K, Mukoyama M, Mori K, Kasahara M, Koshikawa M, Yokoi H, et al. Expression of CCN1 (CYR61) in developing, normal, and diseased human kidney [ J ]. Am J Physiol Renal Physiol, 2007, 293 (4) : F1363-1372.
8Sawai K, Mori K, Mukoyama M, Sugawara A, Suganami T, Koshikawa M, et al. Angiogenic protein cyr61 is expressed by podocytes in anti-Thy-1 glomerulonephritis [ J ]. J Am Soc Nephrol, 2003, 14 (5) : 1154-1163.
9Kagami S, Urushihara M, Kitamura A, Kondo S, Hisayama T, Kitamura M, et al. PDGF-BB enhances alphal betal integrin-mediated activation of the ERK/AP-1 pathway involved in collagen matrix remodeling by rat mesangial cells [ J ]. J Cell Physiol, 2004, 198(3) :470-478.
10Dubey RK, Gillespie DG, Mi Z, Jackson EK. Adenosine inhibits PDGF-induced growth of human glomerular mesangial cells via A (2B) receptors [ J ]. Hypertension, 2005, 46 ( 3 ) :628-634.
